ESPE Abstracts

Background: MiniMed™ 780G was launched in Japan in November 2023 and is expected to further improve glycemic control.Objectives and Methods: 】Subjects of this study were 29 patients with T1DM, aged 2-18 years (average 8.8 years old), who have been treated by SAP using MiniMed™ 770G for at least 3 months prior to switching to 780G smart guard system. We divided subjects into 2 groups by HbA1c levels ove...